Fibroheal Woundcare Pvt ltd, a leader and pioneer in by products utilisation of SILK and first company from India to have commercialised Silk proteins based medical devices in wound management space has raised 6.3 Cr funding from the promoters and a set of new investors including some leading surgeons, medical professionals and bankers. Fibroheal also have a commitment of another 10 Cr from existing and some new investors.

 Fibroheal intends to scale up its go to market, recruit more people, Invest in their future robust pipeline of products in medical devices area and create an impact through the economic multiplier potential of Silk and few other biomaterials. Fibroheal with it’s unique range of products have been healing different types of acute, chronic, traumatic, post operative, non healing or difficult to heal wounds like diabetic ulcers, bed sores, infected C section wounds, accidental trauma etc. The company has a comprehensive range of products including Foams, mesh, powder, particles, adhesive dressings, sprays, gels etc which are already commercialised and are doing well in the market catering to different types and stages of wounds. Currently more than 500 hospitals are using their range of products with presence across 19+ states. Fibroheal also have a strong e-commerce presence on various digital platforms. As a strong R&D driven organisation, they have 20+ academic collaborations with leading institutes across the world and 6+ industrial collaborations with leading names in area of research.

Fibroheal Woundcare Pvt ltd was started on 06th April 2017 by Vivek Mishra & Bharat Tandon later joined by Mr S Subramanian in 2018 as a co-promoter with trio coming together with an aspiration to create research driven comprehensive wound management and tissue reconstruction company catering to different types and stages of wounds using various new age biomaterials including silk.

Fibroheal has 8+ granted patents in hand and few more in process. As a R&D driven startup, Fibroheal collaborated with IISc, Bangalore and supported a student under PMRF program which led to a joint research translation and commercialisation of an external haemostatic product named “Fibroplug” which is a big success and have treated more than 3000 bleeding cases within 4 months of it’s early introduction cum commercialisation. This joint research collaboration highlights the commitment of Fibroheal towards translational research by actively engaging with various leading science institutes across the world and bridging the gap of industry-academia connect.

About this successful funding round closure, one of the earliest believers of Silk and co-founder of Fibroheal Mr Bharat Tandon who led the round said that:- “Congratulations Vivek and whole team of Fibroheal on successful closure of your Pre Series A Fundraise. As earliest backer of Fibroheal which is pioneer in medical application of Silk Proteins, I am happy to have lead this round because I believe the product pipeline which the R&D team is working on is robust and extremely valuable with great potential, Good luck to the entire team”.

What investors said about this round?

Dr KK Narayanan also invested in this round who previously built Metahelix lifesciences which got acquired by Rallis India and co-founded Kottaram Agrofoods (Soulfull cereals) which got acquired by Tata Consumer products sounded his belief on Fibroheal, “Woundcare is a fast growing segment of the health and wellness sector. Fibroheal is poised to become a major player in this sector with a differentiated technology based on ‘Natural Silk’, a committed leadership and a competent team.

Joseph J Thomas a keen investor with over 2 decades of investment experience currently working as Sr Director in India’s largest private banking company said , “The medical devices and healthcare sector is in a very exciting place and there is exponential growth prospects in future. Fibroheal with its cutting edge technology around silk proteins and various medical applications looks very promising.”

Dr Abhishek Vijaykumar, a leading plastic and reconstructive surgeon with a keen interest around medical devices research said “I have been using Fibroheal for about 4 years and the clinical outcome of their wound care products are excellent. They are value of money in comparison to existing imported products from various MNCs. I believe in Fibroheal’s strong and robust R&D pipeline and team. I believe in their CEO,  Vivek Mishra and his competent team to make it one of leading players in medical devices space in India and globe and having watched Fibroheal for 4+ years, I am quite confident about this.

Post this successful investment raise, Harikrishnan PV, CEO, KITVEN Funds exuded confidence in Fibroheal and said that “KITVEN Fund 3 (Biotech) invested in Fibroheal Woundcare Pvt Ltd 1st in 2021 impressed by the potential and promising future in woundcare industry using silk derived proteins. True to our belief, Fibroheal has come a long way in developing unique products. Innovative use of silk based products for wound healing is a ground breaking approach exploring wound healing properties of Silk. The products made from silk has significant advantages over traditional treatments to meet growing demand of effective and affordable woundcare solutions especially for chronic wounds. Overall, Fibroheal is on right path and has potential to create huge impact globally with continued innovation, partnerships and association and we have confidence that company will continue to achieve substantial growth and success in future.

The company was one of the winners of prestigious ELEVATE 100, flagship program of Karnataka government in 2019 under idea2POC program. It was followed by being winner of “Start-up of the year” in 2020 under smart bio awards during Bengaluru Tech Summit 2020. Fibroheal Woundcare Pvt Ltd was also one of the finalists of “National Start-up Awards 2020”

The company was also one of the winners of “NATIONAL AWARD FOR TECHNOLOGY STARTUP 2020” organised by Technology development board, a statutory body under department of science and technology, Govt of India.

The company received early support from BIRAC and Department of Biotechnology and was also winners of LEAP program of BIRAC and got investment through CCAMP (Centre for cellular and molecular platforms).  Earlier in September 2021, KITVEN – Karnataka IT venture fund, the venture capital arm of Karnataka government has made an investment of undisclosed amount in Fibroheal Woundcare Pvt Ltd to ramp up its manufacturing capabilities to cater to the increased expected demands from the market. The whole start-up ecosystem of Government of India including invest India (Startup India), Technology development board, Startup Karntaka, K Tech and Dept of IT,BT and ST has been of great support to Fibroheal all these years and they received adequate support from Centre for Cellular and Molecular platforms, Bangalore Bio innovation Centre, during initial days related to various technical support and doing various studies.

Fibroheal is also backed by EXIM Bank under their “Ubharte Sitaare” Program for building their state of art integrated manufacturing plant & R&D centre which they recently inaugurated in 2024.

The company has previously raised money from existing promoters, Telama Investments, CCAMP and KITVEN.

Fibroheal Woundcare Pvt Ltd works across the value chain of silk growing farmers and have the potential to become an economic multiplier and it fits well with the Vision "Vocal for Local" and “Using local and taking it global”.

Fibroheal has potential to impact many millions in India and across the globe with this sustainable innovation of utilising a local, natural, biodegradable material SILK and healing difficult to heal wounds and leveraging the true economic multiplier potential.